Femasys Inc.

Contributing Author

Recent Articles by Femasys Inc.

Apr-22	Femasys Launches FemaSeed Complete for OB/GYNs at ACOG 2026 FEMY GlobeNewswire
Apr-16	Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio FEMY GlobeNewswire
Apr-01	Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth FEMY GlobeNewswire
Mar-31	Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update FEMY +11.76% GlobeNewswire
Mar-18	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors FEMY GlobeNewswire
Mar-10	Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment FEMY GlobeNewswire
Feb-27	Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FEMY -5.60% FEMY GlobeNewswire
Feb-26	Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access FEMY GlobeNewswire
Feb-23	Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination FEMY GlobeNewswire
Feb-03	Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products FEMY GlobeNewswire
Jan-14	Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement FEMY +17.81% GlobeNewswire
Jan-13	Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed in Community-Based Care FEMY GlobeNewswire
Dec-18	Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device FEMY GlobeNewswire
Nov-14	Femasys Announces Third Quarter Financial Results for 2025 FEMY -11.28% FEMY +8.58% GlobeNewswire
Nov-10	Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe FEMY GlobeNewswire
Nov-03	Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million FEMY GlobeNewswire
Oct-22	Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc Permanent Birth Control in Europe FEMY -9.57% GlobeNewswire
Oct-16	Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo FEMY +35.38% GlobeNewswire
Sep-25	Femasys Accelerates European Growth for FemBloc with Kebomed Partnership FEMY GlobeNewswire
Sep-22	Femasys Partners with Medical Electronic Systems to Launch FemSperm Analysis Kit for use with FemaSeed FEMY GlobeNewswire
Sep-11	Femasys Expands FemSperm Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed FEMY GlobeNewswire
Sep-08	Femasys Secures Regulatory Approval for FemBloc Permanent Birth Control in New Zealand FEMY GlobeNewswire
Sep-02	Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios FEMY +12.62% GlobeNewswire
Aug-25	Femasys Announces Pricing of $8.0 Million Underwritten Public Offering FEMY -27.00% GlobeNewswire
Aug-21	Femasys Announces FemSperm Kit to Activate Gynecologists and Advance FemaSeed Fertility Platform FEMY -8.66% GlobeNewswire
Aug-20	Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control FEMY -7.38% GlobeNewswire
Aug-08	Femasys Announces Second Quarter Financial Results for 2025 FEMY -13.16% FEMY GlobeNewswire
Aug-06	Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion FEMY GlobeNewswire
Jul-01	Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed for First-Line Infertility Treatment and FemVue Diagnostic FEMY GlobeNewswire
Jun-25	Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control FEMY +10.71% GlobeNewswire
Jun-17	Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth FEMY GlobeNewswire
Jun-11	Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations FEMY +6.25% GlobeNewswire
May-30	Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million FEMY -13.73% GlobeNewswire
May-29	Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement FEMY GlobeNewswire
May-08	Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update FEMY -7.83% FEMY GlobeNewswire

Femasys Inc.

Recent Articles by Femasys Inc.

Upgrade your Finviz experience